Patents by Inventor Amy Ripka

Amy Ripka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20170020858
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 26, 2017
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Imidazotriazinone compounds
    Patent number: 9540380
    Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: January 10, 2017
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Richard Chesworth, Gerhard Koenig, Amy Ripka, Gideon Shapiro
  • Compounds for modulating TRPV3 function
    Patent number: 9486455
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 8, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, Magdalene M. Moran, Howard Ng, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20160256447
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: October 7, 2015
    Publication date: September 8, 2016
    Inventors: Magdalene M. Moran, Jayhong A. Chong, Christopher Fanger, Amy Ripka, Glenn R. Larsen, Xiaoguang Zhen, Dennis John Underwood, Manfred Weigele
  • 1,2-disubstituted heterocyclic compounds
    Patent number: 9265767
    Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not to, those associated with cognitive deficits or schizophrenic symptoms.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: February 23, 2016
    Assignee: FORUM PHARMACEUTICALS INC.
    Inventors: Richard Chesworth, Amy Ripka, Gideon Shapiro
  • 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS
    Publication number: 20150344467
    Abstract: 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comparing cognitive deficits or schizophrenic symptoms.
    Type: Application
    Filed: December 19, 2014
    Publication date: December 3, 2015
    Inventors: Amy RIPKA, Gideon SHAPIRO, Richard CHESWORTH
  • PHENOXYMETHYL HETEROCYCLIC COMPOUNDS
    Publication number: 20150322069
    Abstract: Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: November 12, 2015
    Inventors: Amy RIPKA, Gideon SHAPIRO, Richard CHESWORTH
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20150299225
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 22, 2015
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20150274706
    Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
    Type: Application
    Filed: October 31, 2014
    Publication date: October 1, 2015
    Inventors: Richard CHESWORTH, Amy RIPKA, Gideon SHAPIRO
  • Imidazotriazinone Compounds
    Publication number: 20150191476
    Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.
    Type: Application
    Filed: September 18, 2014
    Publication date: July 9, 2015
    Inventors: Matthew Gregory BURSAVICH, Andrew J. MCRINER, Amy RIPKA, Gideon SHAPIRO
  • Phenoxymethyl heterocyclic compounds
    Patent number: 8946222
    Abstract: Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 3, 2015
    Assignee: FORUM Pharmaceuticals Inc.
    Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
  • 1,2-disubstituted heterocyclic compounds
    Patent number: 8933074
    Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 13, 2015
    Assignee: FORUM Pharmaceuticals Inc.
    Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
  • Compounds for modulating TRPV3 function
    Patent number: 8916550
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: December 23, 2014
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • IMIDAZOTRIAZINONE COMPOUNDS
    Publication number: 20140330014
    Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Richard CHESWORTH, Gerhard KOENIG, Amy RIPKA, Gideon SHAPIRO
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20140155417
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: August 30, 2013
    Publication date: June 5, 2014
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis Underwood, Manfred Weigele, Xiaoguang Zhen
  • 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS
    Publication number: 20140038965
    Abstract: 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comparing cognitive deficits or schizophrenic symptoms.
    Type: Application
    Filed: June 17, 2013
    Publication date: February 6, 2014
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: Amy RIPKA, Gideon SHAPIRO, Richard CHESWORTH
  • 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20140011808
    Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 9, 2014
    Inventors: Amy RIPKA, Gideon SHAPIRO, Richard CHESWORTH
  • PDE-10 INHIBITORS
    Publication number: 20130317025
    Abstract: Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative and psychiatric disorders including, but not limited to, those comprising cognitive deficits or schizophrenic symptoms.
    Type: Application
    Filed: June 17, 2013
    Publication date: November 28, 2013
    Inventors: Amy RIPKA, Gideon SHAPIRO, Richard CHESWORTH
  • 5- and 6-membered heterocyclic compounds
    Patent number: 8481534
    Abstract: 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: July 9, 2013
    Assignee: EnVivo Pharmaceuticals, Inc.
    Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
  • PDE-10 inhibitors
    Patent number: 8481532
    Abstract: Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative and psychiatric disorders including, but not limited to, those comprising cognitive deficits or schizophrenic symptoms.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: July 9, 2013
    Assignee: EnVivo Pharmaceuticals, Inc.
    Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth